Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

[Image: see text] While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small-cell lung cancer (NSCLC), most patients will eventually develop resistance to TKIs. In the case of first- and se...

Descripción completa

Detalles Bibliográficos
Autores principales: Eno, Meredith S., Brubaker, Jason D., Campbell, John E., De Savi, Chris, Guzi, Timothy J., Williams, Brett D., Wilson, Douglas, Wilson, Kevin, Brooijmans, Natasja, Kim, Joseph, Özen, Ayşegül, Perola, Emanuele, Hsieh, John, Brown, Victoria, Fetalvero, Kristina, Garner, Andrew, Zhang, Zhuo, Stevison, Faith, Woessner, Rich, Singh, Jatinder, Timsit, Yoav, Kinkema, Caitlin, Medendorp, Clare, Lee, Christopher, Albayya, Faris, Zalutskaya, Alena, Schalm, Stefanie, Dineen, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340769/
https://www.ncbi.nlm.nih.gov/pubmed/35838760
http://dx.doi.org/10.1021/acs.jmedchem.2c00704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340769/
https://www.ncbi.nlm.nih.gov/pubmed/35838760
http://dx.doi.org/10.1021/acs.jmedchem.2c00704

Ejemplares similares